ADMA Biologics is trading $10.19 (+9.99%) after second-quarter earnings on August 5, 2026, showed stronger profitability despite a slight revenue miss.
- ASCENIV revenue rose 24% to $102.9 million.
- Gross margin expanded to 69% from 55% year over year; adjusted EBITDA increased 22% to $61.8 million.
- Trading volume and early-session activity data were unavailable.